DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

Information source: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Sarcoma, Kaposi; HIV Infections

Intervention: Bleomycin sulfate (Drug); Vincristine sulfate (Drug); Doxorubicin hydrochloride (Drug); Zidovudine (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)

Official(s) and/or principal investigator(s):
PS Gill, Study Chair
S Miles, Study Chair

Summary

To study the safety and maximum tolerated dose (MTD) of combined chemotherapy when it is administered to patients with advanced Kaposi's sarcoma together with one of two different doses of zidovudine (AZT). The combination of AZT and chemotherapy may be effective in treating the tumor as well as preventing the life-threatening infections when used for patients with AIDS and Kaposi's sarcoma. The MTD of combined chemotherapy is being determined so that the information will be available for future studies, when the relative effectiveness of the two doses of AZT has been learned.

Clinical Details

Official title: A Phase I Study of Combination Chemotherapy (Adriamycin, Bleomycin, and Vincristine) and Azidothymidine in the Treatment of AIDS Related Kaposi's Sarcoma

Study design: Primary Purpose: Treatment

Detailed description: The combination of AZT and chemotherapy may be effective in treating the tumor as well as preventing the life-threatening infections when used for patients with AIDS and Kaposi's sarcoma. The MTD of combined chemotherapy is being determined so that the information will be available for future studies, when the relative effectiveness of the two doses of AZT has been learned. AMENDED: AZT by mouth. If the treatment is well tolerated, subsequent groups of patients are started on increasing doses of doxorubicin combined with the same dose of bleomycin and vincristine. After determination of the MTD of chemotherapy in combination with AZT, the 2nd phase begins in which AZT is given and the first group of patients is given bleomycin and vincristine only. If this combination is well tolerated, then the subsequent groups are started on increasing doses of doxorubicin with the same dose of bleomycin, vincristine and AZT. The MTD of chemotherapy in combination with AZT is then determined. Patients achieving maximum response to the tumor are maintained on AZT alone. This is an outpatient study, and patients are seen every 2 weeks for evaluation, with a physical examination every month. Original design: The combination of chemotherapy and AZT is given to groups of four patients each, the first group beginning with bleomycin and vincristine, without the addition of doxorubicin. The chemotherapy is given intravenously every 2 weeks. This is combined first with AZT by mouth.

Eligibility

Minimum age: 13 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria Concurrent Medication: Allowed:

- Medication for grades 1 and 2 oral toxicity. Antiemetic agents, except steroids, for

gastrointestinal toxicity. Toxicity grades according to NIAID Recommendations for Grading of Acute and Subacute Toxic Effects (Adults). Patients must demonstrate any of the following clinical and laboratory findings:

- 25 or more mucocutaneous lesions with or without lymphedema.

- Progressive Kaposi's sarcoma (KS) with 10 or more new lesions in the month prior to

study entry or visceral involvement.

- Oral mucosal lesion(s) requiring therapy.

- Prior history of Pneumocystis carinii pneumonia (PCP) or Mycobacterium avium

intracellulare. Patients with any of the following constitutional symptoms with no etiology established may be included:

- Temperature > 38 degrees C and/or drenching night sweats for more than 1 month.

- Watery diarrhea (= or > 3 stools/day) for 2 or more weeks.

- Weight loss > 10 percent of normal. Patients with carcinoma in situ of the cervix or

localized squamous or basal cell carcinoma of the skin may be included. Active alcohol or drug abuse sufficient to prevent adequate compliance with study therapy. Exclusion Criteria Co-existing Condition: Patients with the following conditions will be excluded:

- Peripheral sensory or motor neuropathy.

- Opportunistic infections requiring therapy.

- Significant pulmonary (exertional dyspnea with minimal exercise) or cardiac

insufficiency (New York Heart Association, status > 2).

- Serious neuropsychiatric illness which would prevent informed consent of intensive

treatment. Concurrent Medication: Excluded:

- Any drugs causing anemia, neutropenia, or significant risk of nephrotoxicity.

Patients with a history of other systemic malignancies or lymphomas, except carcinoma in situ of the cervix or localized squamous or basal cell carcinoma of the skin, will be excluded from the study. Prior Medication: Excluded:

- Systemic antineoplastic chemotherapy.

- Excluded within 30 days of study entry:

- Any other investigational therapy.

- Antiretroviral agents (zidovudine, ribavirin).

- Immunomodulating agents (steroids, interferons, naltrexone, isoprinosine, and

interleukin-2).

Locations and Contacts

UCLA CARE Center CRS, Los Angeles, California 90095, United States
Additional Information

Click here for more information about Zidovudine

Related publications:

Brambilla D, Coombs R, Bremer JW, Reichelderfer PS, Kalish L, Shapiro DE. The contributions of assay variation and biological variation to the variability of HIV RNA measurements in serially collected clinical specimens. Int Conf AIDS. 1998;12:805 (abstract no 42163)

Gill PS, Miles SA, Mitsuyasu RT, Montgomery T, McCarthy S, Espina BM, Feldstein M, Levine AM. Phase I AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi's sarcoma. AIDS. 1994 Dec;8(12):1695-9.


Last updated: March 28, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017